Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yihong Deng

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Endocrine|February 2, 2022
Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adultsJuan P Brito, Yihong Deng, Joseph S Ross, et al.
JAMA Internal Medicine|February 28, 2022
Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US AdultsJuan P Brito, Yihong Deng, Joseph S Ross, et al.
Circulation. Cardiovascular Quality and Outcomes|January 8, 2024
Approval, Evidence, and "Off-Label" Device Utilization: The Patent Foramen Ovale Closure StoryAndrew M Goldsweig, Yihong Deng, Xiaoxi Yao, et al.
Ophthalmology. Retina|May 12, 2024
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic RetinopathyAndrew J Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 27, 2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular RiskJoshua J Neumiller, Jeph Herrin, Kavya Sindhu Swarna, et al.
Ophthalmology. Retina|August 7, 2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideAndrew J Barkmeier, Yihong Deng, Kavya Sindhu Swarna, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 4, 2026
Lower Extremity Complications in Adults with Type 2 Diabetes treated with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas: An Emulated Target TrialRozalina G McCoy, Kavya Sindu Swarna, Eric C Polley, et al.
JAMA Network Open|July 24, 2023
Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated ThrombosisIrbaz Bin Riaz, Harry Fuentes, Yihong Deng, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 13, 2025
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease RiskUrja N Kalathiya, Jeph Herrin, Kavya Sindu Swarna, et al.
Endocrine|June 5, 2021
Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine useJuan P Brito, Joseph S Ross, Yihong Deng, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Endocrine|February 2, 2022
Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adultsJuan P Brito, Yihong Deng, Joseph S Ross, et al.
JAMA Internal Medicine|February 28, 2022
Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US AdultsJuan P Brito, Yihong Deng, Joseph S Ross, et al.
Circulation. Cardiovascular Quality and Outcomes|January 8, 2024
Approval, Evidence, and "Off-Label" Device Utilization: The Patent Foramen Ovale Closure StoryAndrew M Goldsweig, Yihong Deng, Xiaoxi Yao, et al.
Ophthalmology. Retina|May 12, 2024
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic RetinopathyAndrew J Barkmeier, Jeph Herrin, Kavya Sindhu Swarna, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 27, 2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular RiskJoshua J Neumiller, Jeph Herrin, Kavya Sindhu Swarna, et al.
Ophthalmology. Retina|August 7, 2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideAndrew J Barkmeier, Yihong Deng, Kavya Sindhu Swarna, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 4, 2026
Lower Extremity Complications in Adults with Type 2 Diabetes treated with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas: An Emulated Target TrialRozalina G McCoy, Kavya Sindu Swarna, Eric C Polley, et al.
JAMA Network Open|July 24, 2023
Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated ThrombosisIrbaz Bin Riaz, Harry Fuentes, Yihong Deng, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 13, 2025
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease RiskUrja N Kalathiya, Jeph Herrin, Kavya Sindu Swarna, et al.
Endocrine|June 5, 2021
Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine useJuan P Brito, Joseph S Ross, Yihong Deng, et al.
Pageof 5